{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:45:35Z","timestamp":1769877935145,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Since the coronavirus disease 2019 (COVID-19) has risen, several risk factors have been identified, predicting a worse outcome. It has been speculated that patients with Multiple sclerosis (MS) have an increased risk for a severe course of COVID-19 due to a suspected higher vulnerability. Therefore, we aimed to analyze the impact of comorbid MS on the outcome of patients with COVID-19 in Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cross-sectional study using the administrative database of all hospitalized patients diagnosed with PCR-confirmed COVID-19 (<jats:italic>n<\/jats:italic>\u00a0=\u2009157,524) in Germany during 2020. The cohort was stratified according to the presence (<jats:italic>n<\/jats:italic>\u00a0=\u2009551) or absence (<jats:italic>n<\/jats:italic>\u00a0=\u2009156,973) of comorbid MS, including discrimination of MS subtypes. Primary outcome measures were admission to the intensive care unit (ICU), use of invasive or non-invasive ventilation, and in-hospital mortality. Differences were investigated using rates and odds ratios as estimates. Pooled overall estimates, sex-stratified estimates, age-group stratified estimates, and MS subtype stratified estimates were calculated for all outcomes under the random-effects model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 157,524 patients hospitalized with COVID-19, 551 had a concurrent MS diagnosis (0.3%). Overall, univariate analysis showed lower rates of ICU admission (17.1% versus 22.7%, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001), lower use of ventilation (9.8% versus 14.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and lower in-hospital mortality (11.1% versus 19.3%, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001) among COVID-19 patients with comorbid MS. This finding was stable across the subgroup analysis of sex and MS subtype but was attenuated by age-stratification, confirming equal odds of in-hospital mortality between COVID-19 patients with and without MS (log OR: 0.09 [95% CI: \u2212\u20090.40, 0.59]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although there might be differences in risk within the MS patients\u2019 population, this large-scale nationwide analysis found no evidence for a worse outcome of COVID-19 in patients with comorbid MS compared to non-MS individuals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42466-021-00143-y","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T05:02:44Z","timestamp":1629090164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany"],"prefix":"10.1186","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-8350","authenticated-orcid":false,"given":"Daniel","family":"Richter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Faissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Bartig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"T\u00f6nges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Ayzenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Krogias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"143_CR1","volume-title":"Novel coronavirus \u2013 China 2020","author":"World Health Organization","year":"2020","unstructured":"World Health Organization (2020). Novel coronavirus \u2013 China 2020. https:\/\/www.who.int\/csr\/don\/12-january-2020-novel-coronavirus-china\/en\/. 30 May 2021."},{"issue":"10","key":"143_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1177\/1352458520941485","volume":"26","author":"LM Peeters","year":"2020","unstructured":"Peeters, L. M., Parciak, T., Walton, C., Geys, L., Moreau, Y., De Brouwer, E., \u2026 Rijke, N. (2020). COVID-19 in people with multiple sclerosis: A global data sharing initiative. Multiple Sclerosis (Houndmills, Basingstoke, England), 26(10), 1157\u20131162. https:\/\/doi.org\/10.1177\/1352458520941485.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"6","key":"143_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","volume":"19","author":"MP Sormani","year":"2020","unstructured":"Sormani, M. P., & Italian Study Group on COVID-19 infection in multiple sclerosis (2020). An Italian programme for COVID-19 infection in multiple sclerosis. The Lancet Neurology, 19(6), 481\u2013482. https:\/\/doi.org\/10.1016\/S1474-4422(20)30147-2.","journal-title":"The Lancet Neurology"},{"issue":"12","key":"143_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","volume":"18","author":"S Faissner","year":"2019","unstructured":"Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019). Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews Drug Discovery, 18(12), 905\u2013922. https:\/\/doi.org\/10.1038\/s41573-019-0035-2.","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"143_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","volume":"52","author":"SL Hauser","year":"2006","unstructured":"Hauser, S. L., & Oksenberg, J. R. (2006). The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron, 52(1), 61\u201376. https:\/\/doi.org\/10.1016\/j.neuron.2006.09.011.","journal-title":"Neuron"},{"issue":"1","key":"143_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/imr.12169","volume":"259","author":"M Kleinewietfeld","year":"2014","unstructured":"Kleinewietfeld, M., & Hafler, D. A. (2014). Regulatory T cells in autoimmune neuroinflammation. Immunological Reviews, 259(1), 231\u2013244. https:\/\/doi.org\/10.1111\/imr.12169.","journal-title":"Immunological Reviews"},{"key":"143_CR7","volume-title":"Welchen Verlauf nimmt COVID-19 bei Patienten mit Multipler Sklerose?","author":"Deutsche Gesellschaft f\u00fcr Neurologie","year":"2020","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (2020). Welchen Verlauf nimmt COVID-19 bei Patienten mit Multipler Sklerose? https:\/\/dgn.org\/presse\/pressemitteilungen\/welchen-verlauf-nimmt-covid-19-bei-patienten-mit-multipler-sklerose\/ 30 May 2021."},{"issue":"13","key":"143_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.15585\/mmwr.mm6913e2","volume":"69","author":"CDC COVID-19 Response Team","year":"2020","unstructured":"CDC COVID-19 Response Team (2020). Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-march 28, 2020. MMWR Morbidity and Mortality Weekly Report, 69(13), 382\u2013386. https:\/\/doi.org\/10.15585\/mmwr.mm6913e2.","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"issue":"5","key":"143_CR9","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","volume":"55","author":"WJ Guan","year":"2020","unstructured":"Guan, W. J., Liang, W. H., Zhao, Y., Liang, H. R., Chen, Z. S., Li, Y. M., \u2026 China Medical Treatment Expert Group for COVID-19 (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. The European Respiratory Journal, 55(5), 2000547. https:\/\/doi.org\/10.1183\/13993003.00547-2020.","journal-title":"The European Respiratory Journal"},{"issue":"18","key":"143_CR10","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., \u2026 China Medical Treatment Expert Group for Covid-19 (2020). Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine, 382(18), 1708\u20131720.","journal-title":"The New England Journal of Medicine"},{"key":"143_CR11","volume-title":"Characteristics of COVID-19 patients dying in Italy","author":"Instituto Superiore di Sanit\u00e0","year":"2020","unstructured":"Instituto Superiore di Sanit\u00e0 (2020). Characteristics of COVID-19 patients dying in Italy. https:\/\/www.epicentro.iss.it\/coronavirus\/bollettino\/Report-COVID-2019_20_marzo_eng.pdf 30 May 2021."},{"issue":"1","key":"143_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42466-020-00069-x","volume":"2","author":"D Richter","year":"2020","unstructured":"Richter, D., Bartig, D., Krogias, C., & T\u00f6nges, L. (2020). Letter to the editor: Risk comorbidities of COVID-19 in Parkinson's disease patients in Germany. Neurological Research and Practice, 2(1), 22. https:\/\/doi.org\/10.1186\/s42466-020-00069-x.","journal-title":"Neurological Research and Practice"},{"key":"143_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s42466-020-00095-9","volume":"2","author":"D Richter","year":"2020","unstructured":"Richter, D., Krogias, C., Eyding, J., Bartig, D., Grau, A., & Weber, R. (2020). Comparison of stroke care parameters in acute ischemic stroke patients with and without concurrent Covid-19. A Nationwide analysis. Neurological Research and Practice, 2, 48.","journal-title":"Neurological Research and Practice"},{"issue":"5","key":"143_CR14","doi-asserted-by":"publisher","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","volume":"7","author":"E Parrotta","year":"2020","unstructured":"Parrotta, E., Kister, I., Charvet, L., Sammarco, C., Saha, V., Charlson, R. E., \u2026 Zhovtis Ryerson, L. (2020). COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center. Neurology(R) Neuroimmunology & Neuroinflammation, 7(5), e835.","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"9","key":"143_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"77","author":"C Louapre","year":"2020","unstructured":"Louapre, C., Collongues, N., Stankoff, B., Giannesini, C., Papeix, C., Bensa, C., \u2026 Videt, D. (2020). Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurology, 77(9), 1079\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2581.","journal-title":"JAMA Neurology"},{"key":"143_CR16","doi-asserted-by":"crossref","unstructured":"Salter, A., Fox, R. J., Newsome, S. D., Halper, J., Li, D., Kanellis, P., \u2026 Cross, A. H. (2021). Outcomes and risk factors associated with SARS-CoV-2 infection in a north American registry of patients with multiple sclerosis. JAMA Neurology, 78(6), e210688.","DOI":"10.1001\/jamaneurol.2021.0688"},{"issue":"7823","key":"143_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41586-020-02483-2","volume":"585","author":"S Mallapaty","year":"2020","unstructured":"Mallapaty, S. (2020). The coronavirus is most deadly if you are older and male - new data reveal the risks. Nature, 585(7823), 16\u201317. https:\/\/doi.org\/10.1038\/d41586-020-02483-2.","journal-title":"Nature"},{"key":"143_CR18","first-page":"m4509","volume":"371","author":"R Pastor-Barriuso","year":"2020","unstructured":"Pastor-Barriuso, R., P\u00e9rez-G\u00f3mez, B., Hern\u00e1n, M. A., P\u00e9rez-Olmeda, M., Yotti, R., Oteo-Iglesias, J., \u2026 ENE-COVID Study Group (2020). Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: Nationwide seroepidemiological study. BMJ (Clinical research ed.), 371, m4509.","journal-title":"BMJ (Clinical research ed.)"},{"issue":"7844","key":"143_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","volume":"590","author":"M O'Driscoll","year":"2021","unstructured":"O'Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D., Azman, A. S., Paireau, J., \u2026 Salje, H. (2021). Age-specific mortality and immunity patterns of SARS-CoV-2. Nature, 590(7844), 140\u2013145. https:\/\/doi.org\/10.1038\/s41586-020-2918-0.","journal-title":"Nature"},{"issue":"1","key":"143_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41467-021-21237-w","volume":"12","author":"H Ward","year":"2021","unstructured":"Ward, H., Atchison, C., Whitaker, M., Ainslie, K., Elliott, J., Okell, L., \u2026 Elliott, P. (2021). SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nature Communications, 12(1), 905. https:\/\/doi.org\/10.1038\/s41467-021-21237-w.","journal-title":"Nature Communications"},{"key":"143_CR21","doi-asserted-by":"publisher","first-page":"175628642110306","DOI":"10.1177\/17562864211030656","volume":"14","author":"D Richter","year":"2021","unstructured":"Richter, D., Faissner, S., Bartig, D., T\u00f6nges, L., Hellwig, K., Ayzenberg, I., \u2026 Gold, R. (2021). The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany. Therapeutic Advances in Neurological Disorders, 14, 175628642110306. In Press. https:\/\/doi.org\/10.1177\/17562864211030656.","journal-title":"Therapeutic Advances in Neurological Disorders"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-021-00143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-021-00143-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-021-00143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T05:04:51Z","timestamp":1629090291000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-021-00143-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["143"],"URL":"https:\/\/doi.org\/10.1186\/s42466-021-00143-y","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No informed consent or ethical approval was required for this study because completely anonymized data were used and provided by the German Federal Statistical Office to comply with the German data protection regulations. The latest Good Practice in Secondary Data Analysis recommendations (version 2; 2008) of the German Working Group for the Survey and Utilization of Secondary Data (with representatives from the German Society for Social Medicine and Prevention and the German Society for Epidemiology) and the Working Group for Epidemiological Methods (with representatives from the German Society for Epidemiology, the German Society for Medical Informatics, Biometry and Epidemiology and the German Society for Social Medicine and Prevention) state in their respective Guideline 1 that \u201c \u2026 recommendation to consult with an ethics committee need not apply to secondary data analyses if all the data protection provisions on pseudo-anonymization of all personal data are fulfilled \u2026 and no link to primary data is intended.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Daniel Richter receives support from the Medical Faculty of Ruhr-University Bochum (FoRUM grant K136\u201320). Simon Faissner received speaker\u2019s and\/or board honoraria from Biogen, BMS, Celgene, Novartis and Roche and grant support from Ruhr-University Bochum, DMSG, Stiftung f\u00fcr therapeutische Forschung and Novartis, none related to this work. Dirk Bartig received orders for analysis of the German Diagnosis-Related Groups system from Boehringer Ingelheim and Sanofi Aventis. Lars T\u00f6nges LT has received travel funding and\/or speaker honoraria from Abbvie, Bayer, Bial, Desitin, GE, UCB, Zambon and consulted for Abbvie, Bayer, Bial, Desitin, Stadapharm, UCB, Zambon in the last 3 years.Kerstin Hellwig: received speaker\u2019s and\/or research support from Biogen, Bayer, Teva, Sanofi Genzyme, Novartis, and Roche and grant support from the Innovation Fond, DMSG and DFG, all not related to this work. Ilya Ayzenberg has received travel grants and speaker honoraria from Biogen Idec and Guthy-Jackson Charitable Foundation, Alexion, Santhera, Merck, served on scientific advisory boards for Roche and Alexion, and received research support from Diamed, none related to this study. Christos Krogias received speaker honoraria or travel grants for scientific meetings from Bayer Vital and Daichii Sankyo. Ralf Gold serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}